Dominik Mumberg
Dominik Mumberg has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Thomas T. Poulsen
Adcendo ApS, Frederiksberg, Denmark
31 shared publications - Pernille Barkholt
Gubra, Hoersholm, Denmark
17 shared publications - Anne Bie
Adcendo ApS, Frederiksberg, Denmark
16 shared publications - Christophe Côme
Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, Turku, Finland
16 shared publications Daniela Pontieri
16 shared publications- Huiyan Shi
Multitude Therapeutics, Shanghai, China
16 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 1. Binding of Isotype Control ADC to TF.
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 1. Binding of Isotype Control ADC to TF.
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Table 1. Cell surface Tissue Factor expression, Ab-T02 and ADCE-T02 binding in cancer cell lines.
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Table 1. Cell surface Tissue Factor expression, Ab-T02 and ADCE-T02 binding in cancer cell lines.
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 2. Structure of Tissue Factor with the tisotumab epitope and the Ab-T02 epitope highlighted.
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 2. Structure of Tissue Factor with the tisotumab epitope and the Ab-T02 epitope highlighted.
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 3. In vitro cytotoxicity of ADCE-T02 in A549 cancer cells and induction of Caspase 3/7 activity in NCI-H292 cells.
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 3. In vitro cytotoxicity of ADCE-T02 in A549 cancer cells and induction of Caspase 3/7 activity in NCI-H292 cells.
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 4. Immunohistochemical staining of cell line derived- and patient derived xenograft tumors.
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 4. Immunohistochemical staining of cell line derived- and patient derived xenograft tumors.
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 5. ADCE-T02 and Total antibody serum concentration over time following dosing in mice.
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 5. ADCE-T02 and Total antibody serum concentration over time following dosing in mice.
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Table 2. Overview of in vivo tumor volume, percent tumor growth inhibition and mouse body weight.
- 11 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Table 2. Overview of in vivo tumor volume, percent tumor growth inhibition and mouse body weight.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 1. Binding of Isotype Control ADC to TF.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Figure 1. Binding of Isotype Control ADC to TF.
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Data from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Tissue factor (TF) protein is involved in activating the extrinsic blood coagulation cascade. TF expression is normally anatomically limited to the perivascular space, but TF is overexpressed in many malignancies, including pancreatic, cervical, prostate, and head and neck cancers, which makes TF an ideal antibody–drug conjugate (ADC) target. The TF-ADC tisotumab vedotin is approved for cervical cancer treatment but induces substantial side effects including ocular toxicities, peripheral neuropathy, and bleeding, limiting its further clinical development and warranting optimized ADC design to improve the therapeutic window. ADCE-T02 is a novel TF-ADC comprising the monoclonal antibody Ab-T02 conjugated via a self-immolative linker to the topoisomerase 1 inhibitor exatecan at an average drug-to-antibody ratio of 4.5. In contrast to tisotumab, Ab-T02 does not inhibit coagulation factor X activation. ADCE-T02 binds TF with high affinity inducing ADC internalization, exatecan release, cancer cell death, and bystander cytotoxicity in vitro. In vivo, ADCE-T02 is highly efficacious across a range of cell line–derived and patient-derived xenograft models including hard-to-treat models with large tumors, resistance to standard of care, low and/or heterogeneous expression of TF, and multidrug resistance. Importantly, ADCE-T02 demonstrates favorable pharmacokinetic properties and is well tolerated in nonhuman primates and in contrast to tisotumab vedotin and other auristatin-based ADCs shows no evidence of ocular, skin, and lung toxicities; peripheral nerve damage; or bleeding. In summary, ADCE-T02 constitutes a novel TF-ADC with a much improved preclinical therapeutic window. Phase I clinical development of ADCE-T02 in patients with advanced solid tumors is ongoing (ClinicalTrials ID: NCT06597721).
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Tissue factor (TF) protein is involved in activating the extrinsic blood coagulation cascade. TF expression is normally anatomically limited to the perivascular space, but TF is overexpressed in many malignancies, including pancreatic, cervical, prostate, and head and neck cancers, which makes TF an ideal antibody–drug conjugate (ADC) target. The TF-ADC tisotumab vedotin is approved for cervical cancer treatment but induces substantial side effects including ocular toxicities, peripheral neuropathy, and bleeding, limiting its further clinical development and warranting optimized ADC design to improve the therapeutic window. ADCE-T02 is a novel TF-ADC comprising the monoclonal antibody Ab-T02 conjugated via a self-immolative linker to the topoisomerase 1 inhibitor exatecan at an average drug-to-antibody ratio of 4.5. In contrast to tisotumab, Ab-T02 does not inhibit coagulation factor X activation. ADCE-T02 binds TF with high affinity inducing ADC internalization, exatecan release, cancer cell death, and bystander cytotoxicity in vitro. In vivo, ADCE-T02 is highly efficacious across a range of cell line–derived and patient-derived xenograft models including hard-to-treat models with large tumors, resistance to standard of care, low and/or heterogeneous expression of TF, and multidrug resistance. Importantly, ADCE-T02 demonstrates favorable pharmacokinetic properties and is well tolerated in nonhuman primates and in contrast to tisotumab vedotin and other auristatin-based ADCs shows no evidence of ocular, skin, and lung toxicities; peripheral nerve damage; or bleeding. In summary, ADCE-T02 constitutes a novel TF-ADC with a much improved preclinical therapeutic window. Phase I clinical development of ADCE-T02 in patients with advanced solid tumors is ongoing (ClinicalTrials ID: NCT06597721).
- Open Access
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Table 1. Cell surface Tissue Factor expression, Ab-T02 and ADCE-T02 binding in cancer cell lines.
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from ADCE-T02: A Next-generation Antibody–Drug Conjugate Targeting Tissue Factor Demonstrates Superior Preclinical Efficacy and Tolerability
Supplementary Table 1. Cell surface Tissue Factor expression, Ab-T02 and ADCE-T02 binding in cancer cell lines.